TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3016764
Drug: Subjective effects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective effects measures (Addiction Research Center Inventory, Single Dose Questionnaire, Visual Analog Scale)
Study: 26002761
Drug: Rotigotine (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (dopamine agonist patch with 24-hour action)
Study: 20079321
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg adalimumab
Study: 16979327
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus (petal) 30 mg/day (BD)
Study: 15580395
Drug: 5 million
Normalized name: colistin 1.5 million UNT Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 million i.u. recombinant interferon alpha-2b (IFNA) administered s.c. in fasted state
Study: 15580395
Drug: 5 million
Normalized name: colistin 1.5 million UNT Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 million i.u. recombinant interferon alpha-2b (IFNA) administered s.c. after semiliquid test meal
Study: 15580395
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered s.c. in fasted state
Study: 15580395
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered s.c. after semiliquid test meal
Study: 11245552
Drug: Desogestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing oral contraceptive (DSG-OC)
Study: 8359179
Drug: Quinidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (250 mg bisulfate) co-administration with Haloperidol (5 mg)
Study: 8359179
Drug: Quinidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (250 mg bisulfate) co-administration with Reduced Haloperidol (5 mg)
Study: 8359179
Drug: Quinidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (250 mg bisulfate) co-administration
Study: 8359179
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 mg) and Reduced Haloperidol (5 mg)
Study: 3521427
Drug: T-cell-depleted bone
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell-depleted bone marrow (using monoclonal anti-T-cell antibody CT-2 and complement)
Study: 31275597
Drug: Lorcaserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin (10 mg twice daily)
Study: 26402941
Drug: Enteral oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral oxygen therapy (oxygen smoothies based on protein-carbohydrate raw materials with dietary fiber), 500 ml daily for 10 days.
Study: 26402941
Drug: Enteral oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral oxygen therapy (oxygen smoothies)
Study: 18805509
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (BID) call schedule
Study: 18805509
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (OD) call schedule
Study: 18805509
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily (TID) call schedule
Study: 17144555
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment including physical factors (ultrasound, sinusoidal modulated currents‐‐SMC) and medicinal suppositories (diklofenak, vitaprost, polyoxidonium)
Study: 17144555
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of physical factors and medicinal suppositories
Study: 11147908
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine administration
Study: 19411798
Drug: RLG (rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLG (rocuronium 0.6 mg/kg mixed with 2 mL of 2% lidocaine)
Study: 19411798
Drug: RSG (rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG (rocuronium 0.6 mg/kg with 8.4% sodium bicarbonate)
Study: 19411798
Drug: RG (rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG (rocuronium 0.6 mg/kg)
Study: 17493669
Drug: NACT+RHPPL (vincristine-cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACT+RHPPL (vincristine-cisplatin chemotherapy every 10 days for 3 cycles before RHPPL)
Study: 11840766
Drug: Attenuated live
Normalized name: Influenza Virus Attenuated Live Trivalent Vaccine (Types A and B) (Avian)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated live hepatitis A vaccine (H2 strain) - 10(6.5) TCID50/ml
Study: 30910634
Drug: Coated tablets
Normalized name: psyllium seed coatings,blond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablets
Study: 30910634
Drug: Uncoated tablet
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated tablet
Study: 24070104
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Therapy for Primary Care (PST‐PC), delivered in 8 weekly telephone sessions of 30-45 minutes duration and 4 monthly maintenance sessions.
Study: 24070104
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (referral to general practitioner for assessment and treatment)
Study: 22443122
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface treatment
Study: 16777920
Drug: Zinc carnosine
Normalized name: Zinc Carnosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc carnosine (ZnC) 37.5 mg twice daily
Study: 11794219
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent split‐virus influenza vaccine
Study: 7819733
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 1 mg betamethasone disodium phosphate and 250 mg piperacillin (group 2)
Study: 3337463
Drug: Albuterol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (4 mg three times daily for 3 days)
Study: 26307337
Drug: Postural manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postural manual therapy (PMT)
Study: 23879752
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (600 mg loading dose followed by 75 mg/day, with open-label aspirin 50-325 mg/day, recommended 162 mg for 5 days then 81 mg daily)
Study: 23879752
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (50-325 mg/day, with a recommended dose of 162 mg for 5 days then 81 mg daily)
Study: 20953211
Drug: rhTNFR-Fc 12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTNFR-Fc 12.5, 25, 37.5, or 50 mg SC injection (healthy volunteers)
Study: 20953211
Drug: rhTNFR-Fc 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTNFR-Fc 25 mg BIW or 50 mg QW (patients with AS)
Study: 18853110
Drug: Kushenin 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kushenin 0.6 g once a day
Study: 16649350
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg) for 3 months
Study: 14662554
Drug: Haloperidol (3-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3-15 mg/d)
Study: 8769301
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU IFN daily until HCV-RNA was undetectable in plasma X 3 over 3 consecutive monthly determinations followed by demonstrated HCV-RNA negativity in liver biopsy tissue
Study: 1570963
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline containing 10 U per 1 mL heparin
Study: 6099649
Drug: Towne live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Towne live, attenuated cytomegalovirus (CMV) vaccine
Study: 25200403
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg daily for 8 weeks
Study: 16411341
Drug: Thai regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thai regimen (zidovudine 300 mg po bid from 36 weeks until labour, zidovudine 300 mg po q3h during labour; neonates received placebo)
Study: 16411341
Drug: Ultra-Short regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-Short regimen (placebo from 36 weeks to labour, zidovudine 300 mg po q3h in labour; neonates received zidovudine 2 mg/kg po qid for the first three days)
Study: 9640061
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for tick-borne encephalitis (exact treatment details not provided)
Study: 17185207
Drug: Contingency contracting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency contracting (CC)
Study: 7734459
Drug: Medication only/CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only/CC
Study: 7734459
Drug: Medication only/NC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only/NC
Study: 2466359
Drug: Oxendolone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxendolone 200 mg weekly
Study: 31659986
Drug: Stent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent treatment (bare metal stents (BMS) or drug-eluting stents (DES))
Study: 31659986
Drug: Stent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent treatment (BMS or DES)
Study: 22623389
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish intake (two 150-g salmon portions/wk)
Study: 1561466
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sustained-release isosorbide 5-mononitrate (5-IMN)
Study: 1561466
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 50 mg of sustained-release isosorbide 5-mononitrate (5-IMN) for 3 weeks
Study: 31162103
Drug: Salvage radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiotherapy with short-term hormone therapy
Study: 31162103
Drug: Salvage radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiotherapy without short-term hormone therapy
Study: 29665130
Drug: Cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail of digoxin (0.25 mg), furosemide (1 mg), metformin (10 mg), and rosuvastatin (10 mg)
Study: 29665130
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug treatments (digoxin, furosemide, metformin, rosuvastatin)
Study: 27178366
Drug: Prednisolone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (250 mg)
Study: 20309531
Drug: Nicotine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (21 mg)
Study: 8756050
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 500 mg quinine base
Study: 8756050
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 500 mg quinine base
Study: 26049126
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT), 4 sessions
Study: 24075759
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (100,000 units oral)
Study: 15031570
Drug: BiPAP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiPAP plus standard therapy (group 1)
Study: 15031570
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (group 2)
Study: 3710290
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (PK 10169)
Study: 29456149
Drug: Universal Medication
Normalized name: STATLOCK UNIVERSAL PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal Medication Schedule (UMS)
Study: 17472802
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment options for ARMD
Study: 16120062
Drug: 0.375 mg
Normalized name: vitamin A 0.375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375 mg triazolam
Study: 368088
Drug: Oxprenolol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (180 to 480 mg daily)
Study: 368088
Drug: Propranolol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (180 to 480 mg daily)
Study: 30036571
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 µg/kg/day i.v. from day 7 post-transplant until neutrophil recovery
Study: 24762094
Drug: Dulaglutide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 2.0 mg
Study: 11880966
Drug: d4T-3TC-NFV (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d4T-3TC-NFV (3 times daily)
Study: 10452470
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid emulsion (1.0 mg/kg per day)
Study: 10452470
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B dextrose (0.5 mg/kg per day)
Study: 7872342
Drug: ACEI (enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (enalapril or lisinopril)
Study: 2222130
Drug: 25% per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% per week taper of short half-life benzodiazepines
Study: 2222130
Drug: 25% per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% per week taper of long half-life benzodiazepines
Study: 30611640
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous distilled water)
Study: 23863909
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of GAD-alum (4D)
Study: 23863909
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of GAD-alum (2D)
Study: 19343928
Drug: EDTA followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA followed by NaOCl treatment
Study: 15037686
Drug: Nasal sumatriptan
Normalized name: sumatriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal sumatriptan (10 mg for 20-39 kg; 20 mg for >40 kg)
Study: 10460981
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment on other foot zones
Study: 2329393
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine oral rinse used as a preoperative rinse and immediate postextraction irrigant
Study: 7247088
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine combined with aerosol placebo
Study: 26869148
Drug: l-theanine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-theanine (200 mg)
Study: 26869148
Drug: caffeine (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: caffeine (160 mg)
Study: 26869148
Drug: theanine-caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: theanine-caffeine combination
Study: 23727083
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg vs Atorvastatin 10 mg
Study: 21856001
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg intravenous ramosetron (group A)
Study: 21856001
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg oral ramosetron (group B)
Study: 21856001
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.1 mg oral and 0.3 mg intravenous ramosetron (group C)
Study: 10574168
Drug: Control Therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Therapy (CT)
Study: 17920916
Drug: Reduced-intensity stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)
Study: 15277909
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg orally and as a patch) administered the night before surgery and on the morning of surgery
Study: 11504278
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg (Days 1-7) and 400 mg (Days 8-28)
Study: 11504278
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg and 400 mg + Methylphenidate 20 mg (Days 22-28)
Study: 8536887
Drug: Budesonide 6
Normalized name: budesonide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 6 mg daily
Study: 8536887
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg daily
Study: 8160597
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (amiodarone or sotalol)
Study: 23870670
Drug: Ragweed MATA
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed MATA MPL (short ragweed pollen allergoid adsorbed to L‐Tyrosine + MPL)
Study: 10793597
Drug: Fenoterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (10 puffs via metered dose inhaler)
Study: 10793597
Drug: Ipratropium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (10 puffs via metered dose inhaler)
Study: 8762211
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (30 mg/day)
Study: 8762211
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard (20 mg twice a day)
Study: 29517671
Drug: McGrath videolaryngoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: McGrath videolaryngoscope (ML group)
Study: 7617471
Drug: Nicardipine (NCR)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (NCR) at doses of 1.0 mg, 1/4 mg, 1/16 mg, or 1/64 mg
Study: 2239717
Drug: Theophylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (400 mg twice a day)
Study: 2856902
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg twice a day)
Study: 2239717
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (theophylline and atenolol)
Study: 684774
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy combined with external irradiation
Study: 31786983
Drug: Esaxerenone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaxerenone 2.5 mg/day
Study: 31786983
Drug: Esaxerenone 5
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Esaxerenone 5 mg/day
Study: 31074576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly automated phone message reminders)
Study: 30392473
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g refined cold-pressed flaxseed oil providing 4.7 g ALA (n 29)
Study: 30392473
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g high-oleic sunflower oil as control (n 30)
Study: 28913833
Drug: Conjoint family‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint family‐based treatment (FBT)
Study: 28913833
Drug: Parent‐focused treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent‐focused treatment (PFT)
Study: 19203564
Drug: 0.03% meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% meloxicam solution (1 drop t.i.d. for 30 days)
Study: 19203564
Drug: 0.1% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% diclofenac solution (1 drop t.i.d. for 30 days)
Study: 17577461
Drug: CS-706 10
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-706 10 mg
Study: 17577461
Drug: CS-706 50
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-706 50 mg
Study: 17577461
Drug: CS-706 100
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-706 100 mg
Study: 17577461
Drug: CS-706 200
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-706 200 mg
Study: 12561647
Drug: Allergenic extract
Normalized name: ALLERGENIC EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergenic extract pollen Cynodon dactylon (L) Pers skin prick test
Study: 9660536
Drug: Intermittent schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent schedule (IS), oral administration of UFT (130 mg/m2/b.i.d.) with 2 days rest a week
Study: 9660536
Drug: Continuous schedule
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous schedule (CS), consecutive administration of UFT (130 mg/m2/b.i.d.)
Study: 2501967
Drug: Subcutaneous infusion
Normalized name: subcutaneous infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion of GHRH (1-29)NH2 at doses of 5 and 10 micrograms/kg/hour
Study: 2501967
Drug: Oral pyridostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pyridostigmine 60 mg
Study: 367457
Drug: Agar (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agar (1 g/kg/day) orally in 4 daily doses from the 1st to the 5th day of life
Study: 29308939
Drug: Kinesio Taping®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping® (standard treatment plus application of Kinesio Taping® on the respiratory muscles)
Study: 29308939
Drug: Control (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (medication and standard physiotherapy treatment)
Study: 27749236
Drug: Anti-TNF inhibitors
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF inhibitors